Patrick Campbell

Presented at Obesity Week 2023, SURMOUNT-3 provides new insight into the effects of tirzepatide in patients with overweight or obesity.

A highlight of different sessions, presentations, and conversations focused on trends and impact of disparities in women's heart health at HFSA 2023.

Alex Hajduczok, MD, provides perspective on the new GUIDE-HF trial data presented at HFSA 2023.

A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.

Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

Ahmad Masri, MD, MS, offers perspective om the study design of the ACACIA-HCM trial and the unmet need within nonobstructive hypertrophic cardiomyopathy.

Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.

Ankeet Bhatt, MD, MBA, offers perspective into the results of a recent analysis of the GWTG-HF registry at HFSA 2023.

Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.

On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.

A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.

A new study suggests implementation of a low-cost clinical decision support tool reduces hypoglycemia risk in older adults with type 2 diabetes.

A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.

The FDA warns semaglutide (Ozempic) users of increased ileus risk and hypoglycemia with insulin secretagogues.

A 20-year analysis reveals over 25% of US adults have cardiac, renal, or metabolic conditions, with disparities in age and race.

A study from UCSD highlights how advances in imaging modalities and utilization could aid in the early detection of psoriatic arthritis.